Atorvastatin lowers 68Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes
Authors' conclusion
68Ga-DOTATATE uptake across the cardio-haematopoietic axis was lower after statin therapy in individuals with type 2 diabetes. Therefore, 68Ga-DOTATATE is promising as a metric for vascular and haematopoietic inflammation in intervention studies using anti-inflammatory therapeutics in individuals with type 2 diabetes.
Study context
- Population
- Individuals aged >50 years with T2D; mean age 63.2±6.4 years, 82% male, LDL-C 3.42±0.81 mmol/l, HbA1c 55±12 mmol/molcompleted both scans
- Participants
- 22 individuals
- Comparison
- Post vs pre atorvastatin 40 mg once daily for 3 months
- Outcome
- Difference in coronary 68Ga-DOTATATE uptake, expressed as TBR
- Follow-up
- 3 months
Methodological detailsbefore–after comparison
- Before–after comparison
Main finding
As reported in the abstract
Coronary 68Ga-DOTATATE uptake, maximum TBR
Maximum target-to-background ratio (TBR) in coronary arteries lower post statin treatment vs baseline
−31%
95% CI −50, −12
Secondary outcomes
Bone marrow 68Ga-DOTATATE uptake (standardised uptake value (SUV)) · 3 months
- Mean percentage reduction post statin treatment; significantly lower
- −15% (95% CI −27, −4)
Splenic 68Ga-DOTATATE uptake (SUV) · 3 months
- Mean percentage reduction post statin treatment; significantly lower
- −17% (95% CI −32, −2)
Original publication
Atorvastatin lowers 68Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes. Diabetologia. Published 15 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →